Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic faecal microbiota, pooled
- Development stage
- Unknown
- Lead developer
- MaaT Pharma
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Rectal
01
Overview
Allogeneic faecal microbiota, pooled, is an investigational microbial therapy developed by Assistance Publique - Hôpitaux de Paris (AP-HP). It consists of a standardized preparation of fecal microbiota collected from multiple healthy allogeneic donors and pooled to increase microbial diversity and reduce donor-dependent variability. The therapy is primarily being evaluated for the treatment of primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD), including ulcerative colitis. The mechanism of action involves the restoration of a healthy gut microbiome in patients with dysbiosis, which in turn modulates the mucosal immune system, displaces pathogenic bacteria, and potentially corrects metabolic imbalances, such as altered bile acid profiles, that contribute to the pathogenesis of chronic inflammatory and cholestatic liver diseases.
- Other names
- pooled fecal microbiota transplantationpooled FMTallogeneic FMTstandardized pooled FMT
Beyond the preview
Go deeper on allogeneic faecal microbiota, pooled.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic faecal microbiota, pooled.